Background and objective: GH and IGF-I exert an important role in the control of bone formation, as shown by decreased bone mineral density and increased fracture risk in adult hypopituitary patients untreated for GH deficiency (GHD). Different degrees of bone demineralization are frequently reported in patients affected by β-thalassaemia. Considering the high prevalence of GHD recently observed by our group among adult thalassaemic patients, we elected to study the possible role of GH-IGF-I abnormalities in the pathogenesis of the osteopenia/osteoporosis of this disease. Design: Sixty-four adult thalassaemic patients (49 with thalassaemia major and 15 with thalassaemia intermedia, 23 men and 41 women, aged 31.4 ± 6.8 years) were studied. M...
Management of thalassemia major has shown substantial clinical and prognostic improvement, suggestin...
β-thalassemia is the most common single gene disorder worldwide, in which hemoglobin β-chain produc...
BACKGROUND: Osteoporosis is a leading cause of morbidity in patients affected by β-thalassemia major...
Previous evidence supports a role for growth hormone (GH)\u2013insulin-like growth factor (IGF)-I de...
Introduction: Bone disease and short stature are frequent clinical features of patients with beta-th...
Background: Dysfunction of GH-IGF-I axis has been described in many patients affected by β-thalassem...
Despite the extraordinary improvements carried out in diagnostic and therapeutic management of thala...
BACKGROUND AND OBJECTIVE: Short stature and growth hormone deficiency (GHD) are frequent occurrences...
With the optimization of transfusional and chelation regimens, beta-thalassemia has changed from a p...
Reduced bone mineral density (BMD) has been reported in patients with isolated GH deficiency (GHD) o...
With the optimization of transfusional and chelation regimens, beta-thalassemia has changed from a p...
Introduction: Insulin-like growth factor 1 (IGF-1) is a key peptide involved in cell growth and pro...
Introduction b-thalassemia (bT) is associated to several endocrine abnormalities mainly due to iron...
We studied bone mass and metabolism in 30 adult women (age 28.5 +/- 1.3) with thalassemia major (TM)...
Background: Osteoporosis is a leading cause of morbidity in patients affected by β-thalassemia major...
Management of thalassemia major has shown substantial clinical and prognostic improvement, suggestin...
β-thalassemia is the most common single gene disorder worldwide, in which hemoglobin β-chain produc...
BACKGROUND: Osteoporosis is a leading cause of morbidity in patients affected by β-thalassemia major...
Previous evidence supports a role for growth hormone (GH)\u2013insulin-like growth factor (IGF)-I de...
Introduction: Bone disease and short stature are frequent clinical features of patients with beta-th...
Background: Dysfunction of GH-IGF-I axis has been described in many patients affected by β-thalassem...
Despite the extraordinary improvements carried out in diagnostic and therapeutic management of thala...
BACKGROUND AND OBJECTIVE: Short stature and growth hormone deficiency (GHD) are frequent occurrences...
With the optimization of transfusional and chelation regimens, beta-thalassemia has changed from a p...
Reduced bone mineral density (BMD) has been reported in patients with isolated GH deficiency (GHD) o...
With the optimization of transfusional and chelation regimens, beta-thalassemia has changed from a p...
Introduction: Insulin-like growth factor 1 (IGF-1) is a key peptide involved in cell growth and pro...
Introduction b-thalassemia (bT) is associated to several endocrine abnormalities mainly due to iron...
We studied bone mass and metabolism in 30 adult women (age 28.5 +/- 1.3) with thalassemia major (TM)...
Background: Osteoporosis is a leading cause of morbidity in patients affected by β-thalassemia major...
Management of thalassemia major has shown substantial clinical and prognostic improvement, suggestin...
β-thalassemia is the most common single gene disorder worldwide, in which hemoglobin β-chain produc...
BACKGROUND: Osteoporosis is a leading cause of morbidity in patients affected by β-thalassemia major...